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national journals, data from local or national 
surveys in original language conveyed by 
local experts, and expert perspectives about 
CAM availability, quality, use and popularity 
in their countries. According to this study, 
conducted in 20 European countries, 56% of 
the European population in general has used 
CAM at least once during the year preced-
ing the survey. For the pediatric population 
the rate was similar (52%), confirming the 
growing interest in CAM reported by pe-
diatricians and institutions. Homeopathy 
and herbal medicine was identified as the 
most popular CAM therapies in Europe [3].
In the United States the percentage of 
healthy children seen in outpatient pediatric 
clinics that uses CAM is between 20-40% 
and rises to values above 50% in the case of 
children with chronic diseases, almost always 
in conjunction with mainstream care [4].
An interesting analysis on the extent of 
homeopathic prescriptions in children was 
conducted by Ekins-Daukes and colleagues 
IntroduCtIon
The National Institutes of Health (NIH) 
has defined complementary and alternative 
medicine (CAM) as “a group of diverse med-
ical and health care systems, practices, and 
products that are not presently considered 
to be part of conventional medicine” [1,2]. 
The National Center for Complementary 
and Alternative Medicine (NCCAM) clas-
sifies CAM therapies into five categories: 
alternative medical systems (homeopathic 
and naturopathic, Chinese, and Ayurvedic 
medicine), mind-body interventions, bio-
logically based therapies (herbs, foods, etc.), 
manipulative and body-based methods, en-
ergy therapies [1,2].
In recent decades the use of CAM has in-
creased significantly, not only among adults 
but also in the pediatric population.  
Zuzak et al. recently conducted a pan-Eu-
ropean review about CAM in pediatrics, re-
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in Scotland. Majority of these prescriptions 
were made for children under 1 year of age 
(8.0/1000 registered children) and the most 
common conditions for which homeopathic 
medicines were prescribed were colic (85%), 
cuts and bruises (52%), teething (49%), der-
matological conditions (32%), earache (21%), 
influenza and upper respiratory tract infec-
tions (16%), cough (16%), vomiting (16%), 
irritability (15%) and diarrhea (12%) [5].
Recently an international survey was 
performed in order to provide insights 
into physician’ attitude towards the use of 
homeopathy and natural remedies in pe-
diatric practice. 582 general pediatricians 
and general practitioners treating pediatric 
conditions in 6 countries (Germany, Spain, 
Russia, Bulgaria, Colombia, Israel) were in-
volved. Herbal medicine and homeopathic 
products amounted to 17% and 15% of to-
tal prescriptions in pediatrics, respectively. 
Upper respiratory tract infections (URTIs), 
infant colic, sleep disturbances and recurrent 
infections were the main causes for which 
natural remedies and homeopathic products 
were used. In the majority of cases they are 
used as complementary treatment together 
with conventional drugs. The study confirms 
high interest of physicians in natural rem-
edies and homeopathy, however their knowl-
edge level is heterogeneous. The concern 
about side effects and the use for themselves 
are the main factor that drives parents to the 
use of homeopathy and natural remedies [6].
Perceived efficacy of homeopathic or natu-
ral treatments, fear of drug adverse effects, 
dissatisfaction with conventional medicine, 
and the need for more personal attention are 
the main reasons given by parents who treat 
their children with homeopathy [4].
Recognizing the increasing use of CAM 
in children, many institutions, like the 
American Academy of Pediatrics (AAP), 
have decided to provide information and 
support for health professionals. In the 
2001 AAP Periodic Survey of Fellows, 73% 
of pediatricians agreed that it is the role of 
pediatricians to provide patients/families 
with information about all potential treat-
ment options for the patient’s condition, 
and 54% agreed that pediatricians should 
consider the use of all potential therapies, 
not just those of mainstream medicine, when 
treating patients [7].
Efforts to include education and training 
for CAM therapies in medical school pro-
grams have also become popular in some 
European countries [8,9].
Despite the long tradition of homeopathy, 
and its spread around the world, the debate 
on this issue is always very heated. In recent 
years a number of studies have been pub-
lished on the effectiveness of homeopathy 
in children. For example, several studies 
conducted in different countries on the man-
agement of acute respiratory infections and 
acute otitis media showed a significant rapid 
improvement upon homeopathic medica-
tions compared to conventional treatment 
and less use of antibiotics [10-12].
Some researchers have highlighted an 
interesting peculiarity: publication bias in 
CAM research is «opposite that of conven-
tional medicine; that is, negative studies are 
more likely to be published in well-known 
journals, and positive studies are more likely 
to be published in non-English language 
and often complimentary medicine jour-
nals» [13].The most controversial aspect of 
homeopathy is the ultra-dilutions and the 
lack of solid data on the mechanism of ac-
tion. Theories on the possible explanation 
of mechanism of action of homeopathy 
within the context of nanomedicine have 
been recently published, although still hotly 
debated [14]. A recent publication by Rut-
ten et al. explores the current evidence for 
homeopathy reporting three meta-analyses 
by Kleijnen, Linde and Cucherat published 
from 1991-2000 that reached positive con-
clusions and a review by Shang in 2005 that 
reached negative conclusions [15-19].
In the present paper the use of natu-
ral and homeopathic remedies for the 
treatment of children ailments are consid-
ered. In particular we focus on minor disor-
ders of early childhood with a major impact 
on the well-being of the whole family namely 
infant colic, teething, upper respiratory tract 
infections (URTIs) and tonsillopharyngitis. 
The results of recent studies on homeopathic 
products for the treatment of these disorders 
are presented and discussed [20-24].
InfAnt ColIC
definition
A common definition of infantile colic 
comes from Morris A. Wessel and col-
leagues, the so-called “rule of 3”: a condi-
tion of a healthy, well-fed baby in which it 
shows periods of intense, unexplained cry-
ing lasting more than at least 3 hours a day, 
on at least 3 days (per week), of at least 3 
weeks [25].
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The prevalence of infantile colic given in 
the scientific literature widely varies and 
ranges from 5-40%, depending on the study 
methodology, the population and the defini-
tion of infantile colic used [26].
Although benign and self-limiting, it is 
associated with higher levels of maternal 
stress and anxiety: the impact of prolonged 
and inconsolable crying in children with in-
fantile colic causing sleepless nights, stress, 
frustration and exhaustion, especially in 
first-time parents [27-29].
Despite being a very common disorder, 
the causes are not yet completely clarified. 
Etiopathology of this condition includes 
both gastrointestinal and non-gastrointes-
tinal factors, such as hypersensitivity to baby 
formula, alteration in gut microflora, exces-
sive gas in the intestine, intestinal hypo- / 
hypermotility, immature digestive system, 
over-stimulation and (hyper-)sensitivity to 
the environment, reflection of problems in 
parent-infant interaction, maternal smoking.
treatment
The above possible causes of infantile colic 
have led to a variety of available treatments, 
ranging from pharmaceutical therapies, di-
etary interventions, behavioral strategies, 
and physical remedies. At first, the most 
commonly recommended approach is to 
discuss the usually natural and self-limiting 
character of infantile colic with parents and 
to offer some methods to parents for calm-
ing the baby.
Pharmaceutical therapies includes simeth-
icone, dicyclomine hydrochloride and cime-
tropium bromide, but results from literature 
on simethicone and dicyclomine for infantile 
colic do not suggest these to be fully effective 
or appropriate treatment options [30-33]. 
A trial by Savino et al. found cimetropium 
bromide more effective than placebo in re-
ducing the duration of crying in children 
with infantile colic but there were reported 
side effects in terms of increased sleepiness 
[34,35]. Safety is a critical issues in infants, 
and a major concern for parents: in literature 
there have been reports of infants who expe-
rienced serious adverse events, such as seri-
ous respiratory symptoms seizures, syncope, 
pulse rate fluctuations and muscular hypo-
tonia after taking dicyclomine hydrochlo-
ride syrup; no causal relationship has been 
established but dicyclomine hydrochloride is 
now contraindicated in infants < 6 months 
and in nursing mothers [35,36]. Recent re-
search is now targeting the promising role 
of Lactobacillus reuteri in the treatment of 
infantile colic [37,38].
Nutritional interventions are closely re-
lated to the type of feeding received by the 
child. In case of breast-fed infants, a moni-
tored low allergen maternal diet avoiding 
cow’s milk and dairy food with appropri-
ate intake of vitamins and minerals may be 
suggested, while the first-line for bottle-fed 
infants is represented by formulas based on 
partially hydrolyzed whey proteins with pre-
biotic oligosaccharides [39].
A considerable number of behavioral 
strategies and physical remedies resulting 
from tradition and practical experience are 
suggested, such as offering an atmosphere of 
security to the baby, decreasing stimulation, 
offering “white noise”, massaging or rock-
ing the baby. Despite the lack of evidence 
published in the literature, this type of rem-
edies may be useful for some children [39].
In the absence of standard of care for 
treatment of infant colic, CAM has assumed 
an increasingly important role in the man-
agement of infantile colic. In particular, it 
is recognized the use of herbal supplements 
(i.e. containing chamomile, fennel, vervain, 
licorice, balm-mint) [40,41] and homeo-
pathic products [42].
Colikind® (use and dosage)
Colikind® (Deutsche Homöopathie 
Union, DHU, Karlsruhe, Germany) is natu-
ral combined medication that is indicated 
for the treatment of infantile colic and flat-
ulence. It is composed of a combination of 
5 single remedies: Chamomilla D6, Cina 
D6, Colocynthis D6, Lac defloratum D6 
Active ingredient therapeutic action / characteristics
Chamomilla D6  y Infant colic with flatulence (infant gaseous colic)
 y Hypersensitivity to pain
 y Restlessness together with dissatisfaction
Cina D6  y Spasms of the gastrointestinal tract
 y Aversion to breast-milk (ingestion causes colic and 
diarrhoea; the baby frequently spits up sour milk)
 y Marked irritability, physical and mental
Colocynthis D6  y Colic / colicky pain better by pressure and heat (warm 
applications)
 y Griping pain around the navel
Lac defloratum D6  y Digestive disorders due to intolerance of milk
 y General aggravation of symptoms from drinking milk
Magnesium 
chloratum D6
 y Constipation with dry, pellet-like stool
 y Problems to digest milk (especially during difficult 
dentition)
table I. Colikind® 
active ingredients and 
therapeutic action
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and magnesium chloratum D6 [43]. In Ta-
ble I Colikind® active ingredients and ther-
apeutic action are reported.
Colikind® is available in drops. The 
medication can be used on its own or in 
combination with prescribed medication. 
Colikind® drops should be kept within 
the mouth before swallowing. In babies 
and small children, the drops can also be 
diluted in a little bit of water and admin-
istered with a plastic spoon. An interval of 
approximately 30 minutes should be kept 
between the intake of Colikind® and eat-
ing or drinking [43].
In case of acute condition, Colikind® can 
be administered at a dose of 3 drops up to 
a max. of 6 times a day; after improvement, 
treatment can be continued with 3 drops 3 
times a day [43].
from literature
In 2010 an open, prospective, multicenter, 
comparative study on Colikind® was pub-
lished by Ilyenko and colleagues [20]. Aim 
of the study was the evaluation of the effec-
tiveness, safety and tolerability of Colikind® 
compared to Simethicone in children with 
infantile colic and/or meteorism. The study 
population was 200 pediatric patients aged 
2 months to 6 years of both sexes. Table II 
summarized the treatment options.
Comparative evaluation of the efficacies 
of the study agents was performed in terms 
of changes in the severity of subjective com-
plaints and objective symptoms at 3, 7, and 
10 day after the start of treatment. In Table 
III subjective complaints and objective 
symptoms are reported. Clinical symptoms 
were assessed by the physician at each visit, 
while overall outcome of treatment, treat-
ment satisfaction, safety and tolerability of 
study medication were assessed both by phy-
sicians and parents. 
On day 10, both treatment groups showed 
a significant improvement of their subjective 
and objective symptoms, whereas Colikind® 
showed to be significantly more effective 
(p < 0.0001). Consequently, the decrease 
Colikind® group (n=100) Simethicone group (n=100)
Children 0-6 years
Acute symptoms: 3 drops / hour (max. 6 times a day)
Afterwards: 3 drops 3 times a day
1 measuring spoon of the emulsion taken 3-5 times 
a day during meals (from a baby bottle or mixed 
with food and drink)
table II. Treatment 
options [20]
Subjective complaints  y Unexplained restlessness
 y Sleep and appetite disturbances
 y Increased crying while feeding
 y Regurgitation
 y Vomiting
 y Stool softening
 y Constipation and flatulence
objective symptoms  y Abdominal bloating
 y Intestinal rumbling
 y Tenderness and intestinal spasm on palpation
 y Changes in stool
 y Dryness of the skin and mucosa
 y Skin pallor
 y Coating and geographism of the tongue
table III. Subjective 
complaints and objective 
symptoms assessed in the 
study [20]
figure 1. Decrease 
in total sum score 
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in total sum score (subjective complaints + 
objective symptoms) was more pronounced 
in the group of children treated with Co-
likind® (Figure 1).
After 10 days of treatment, 96 % of pa-
tients treated with Colikind® showed a “re-
mission” or a “significant improvement” of 
symptoms according to the physicians’ as-
sessment (Figure 2).
Parents’ assessment of overall outcome 
after 10 days of treatment with Colikind® 
was even better.
In total, 98 % benefitted from the treat-
ment with Colikind® - there of 75 % of 
patients showed a “remission” of symptoms 
(Figure 3).
figure 2. Overall 
outcome of treatment 
on day 10, assessed by 
physicians. Adapted 
from [20]
figure 3. Overall 
outcome of treatment 
on day 10, assessed by 
parents. Adapted from 
[20]
Significantly more parents were “very sat-
isfied / satisfied” with treatment in the Co-
likind® group compared to the Simethicone 
group (p < 0.001). In addition, none of the 
parents in the Colikind® group was “dissatis-
fied” with treatment, whereas this applied to 
22 % of parents in the Simethicone group. 
Tolerability of Colikind® was rated “very 
good” or “good” in all patients, whereas in the 
Simethicone group, there were 6 % of par-
ents and 7 % of physicians who rated toler-
ability only as “satisfied”. In the study group 
treated with Colikind® 1 adverse event (AE) 
but no drug-related AE (i.e. adverse drug re-
action (ADR)) was reported. In the control 
group 5 children (5/100, 5 %) treated with 
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Simethicone were observed to suffer from an 
AE, whereas 1 event was assessed as being 
related to the intake of Simethicone (ADR).
According to the results of this study, both 
medications (Colikind® and Simethicone) 
were effective and safe and can thus be rec-
ommended. However the Authors high-
lighted that in the Colikind® group more 
benefits were reported, such as quicker re-
mission, faster decrease in the degree of the 
severity of subjective complaints and objec-
tive symptoms, the greater parents’ satisfac-
tion, the tolerability and the excellent safety 
profile of Colikind®, emphasized by the lack 
of adverse drug reaction.
teethIng
definition
Teething is known as a natural process 
by which the first teeth appear in children. 
A variety of symptoms has been shown to 
accompany teething, including fever, pain, 
irritability, sleep problems, mouthing/bit-
ing, drooling, decreased oral intake, gum 
inflammation, runny nose, and diarrhea [44].
The onset of the primary incisors is usu-
ally around 6-12 months: in the same period 
the circulating maternal humoral immunity 
decreases, and the child’s own humoral im-
munity develops [45]. The simultaneous 
presence of these events often makes this 
period difficult and distressing for both the 
child and their respective parents and ac-
companied by a number of relatively minor 
symptoms [45]. Teething symptoms in chil-
dren can create much distress in parents [21].
treatment
There are many remedies used by parents 
to relieve the symptoms of teething, often 
derived from tradition or experience of 
friends and family.
Pharmacological therapies include topical 
local anesthetics (i.e. lidocaine based prepa-
rations and topical benzocaine gel), topical 
choline salicylate-based products, and sys-
temic analgesics. However, a standard of 
care is not established in the treatment of 
teething disturbances, use of some medica-
tions might be associated with unwanted 
side effects and for some topical teething 
gels cases of potential life-threatening risks 
have been reported [21,46]. In 2011 the US 
Food and Drug Administration (FDA) has 
released a document to recommend not to 
used benzocaine products on children < 2 
years without medical advice [47].
Non pharmacological remedies include 
teething rings, pacifier, hard food like bread, 
frozen fruits and vegetables. The relief de-
rived from the low temperature of the ob-
jects, that cause local vasoconstriction, and by 
the pressure exerted on the gums through the 
biting on hard objects [21,45]. These rem-
edies are widely used and have few contra-
indications. It is crucial, however, to be very 
careful to avoid the chocking risk. It is also 
recommended to use only sugar-free objects 
and not to add medicine to food or feeding 
bottles, as their dosage cannot be checked.
dentokind® (use and dosage)
Dentokind® (Deutsche Homöopathie-
Union, DHU, Karlsruhe, Germany) is a 
complex homeopathic product containing 
five individual homeopathic substances: 
Belladonna D6, Chamomilla D6, Ferrum 
phosphoricum D6, Hepar sulfuris D12 and 
Pulsatilla D6 [48]. It is indicated for the 
treatment of teething symptoms such as ir-
ritability, restlessness, earache, painful gums, 
mild fever and softened stools in babies and 
children. It is available as tablets allowed to 
dissolve slowly in the mouth. For usage in 
small children, tablets can be dissolved in a 
little bit of water. For children < 1 year the 
suggested dosage is 1 tablet every hour, up 
to a maximum of 6 tablets a day, in acute 
condition; the treatment can be extended 
after improvement at a dosage of 1 tablet, 3 
times a day. For children 1-6 years the sug-
gested dosage is 2 tablets every hour, up to a 
maximum of 12 tablets a day, in acute con-
dition; the treatment can be extended after 
improvement at a dosage of 2 tablet, 3 times 
a day. An interval of at least half an hour to 
meals should be kept [48].
from literature
In 2015 a prospective, multicenter, ran-
domized, open-label, comparative, con-
trolled clinical trial on the clinical use of 
Dentokind® was published by Jong and col-
leagues [21]. The study, required for Dento-
kind® marketing authorization in Russian 
Federation, compared Dentokind® to an-
other homeopathic product already autho-
rized in the Federation. The study popula-
tion consisted of 200 pediatric patients up 
to 6 years of age.
Dentokind® was administered orally for 
seven days. Children aged up to one year 
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received Dentokind® tablets with a dos-
age regime of one tablet every hour up to 
six tablets per day (acute symptoms). After 
symptoms reduced one tablet three times a 
day was administered. Children aged 1-6 
years received two tablets every hour up to 
a maximum of twelve tablets per day (acute 
symptoms). After symptoms reduction the 
dosage was two tablets three times per day. 
The other homeopathic medication was 
administered rectally for a period of seven 
days. For children aged up to six months the 
maximum daily dose was two suppositories 
a day. Children older than six months of age 
received a maximum of four suppositories 
(at a body temperature of ≥ 37.5°C) a day. 
When body temperature normalized one 
suppository was used for further 3-4 days 
1-2 times per day (with preventive purpose).
Primary endpoints were changes in total 
severity scores of subjective complaints 
(TSSC) and changes in total severity scores 
of clinical signs (TSCS) after treatment with 
study medication for 3-5-7 days. In Table 
IV subjective complaints and clinical signs 
are reported.
In the Dentokind group the assessment of 
TSCC recorded a reduction from 7.0 (base-
line median value) to 3.0 (Day 3-5) and 1.0 
at Day 7, while in the control group TSSC 
values decreased from 5.0 (baseline median 
value) to 3.0 (Day 3-5) and 1.0 at Day 7.
The study showed a reduction also in the 
TSCS values, which decreased from 6.0 
(baseline median value) to 3.0 (Day 3-5) and 
1.0 (Day 7) in the Dentokind group, and 
from 5.0 (baseline median value) to 4.0 (Day 
3-5) and 1.0 (Day 7) in the control group.
Subjective complaints  y Unmotivated anxiety
 y Gingival tenderness and appetite disorder
 y Otalgy
 y Stool softening
 y Sleep-onset insomnia and frequent awakenings
Clinical signs  y Skin pallor
 y Gingiva hyperemia
 y Gingiva swelling
 y Hematoma and hyperemia around the mouth
 y Drooling and hyperthermia
table IV. Subjective 
complaints (TSSC) and 
clinical signs (TSCS) 
assessed in the study 
[21]
figure 4. Overall 
outcome on day 7, 
assessed by physicians. 
Adapted from [21]
Improvement of individual complaints 
and individual signs after 7 days of treatment 
was observed in both treatment groups-ex-
cept for the complaint sleep-onset insom-
nia. Compared to the other homeopathic 
medication improvement of the individual 
complaints gingival tenderness and appetite 
disorder and of the signs gingival hyperemia 
and gingival swelling was observed in sig-
nificantly more children of the Dentokind® 
group (Armitage Trend Test: p<0.05; FAS).
After 7 days of treatment children treated 
with Dentokind® had a 5-times higher odds 
of showing improvement in total severity 
score of subjective complaints than children 
treated with the other homeopathic medica-
tion and a 2.5-times higher odds of showing 
improvement in the total severity score of 
objective clinical signs.
After 7 days of treatment with Dento-
kind® almost all parents and investigators 
(n=99 out of 100 each) of the Dentokind® 
group rated “no complaints” or “major im-
provements” (Figure 4). Almost all parents 
(n=99 out of 100) of the Dentokind® group 
were very satisfied or satisfied with the 
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treatment. In comparison with the other 
product, the treatment satisfaction in Den-
tokind® group was significantly better (Ar-
mitage Trend Test: p<0.0001; FAS) (Figure 
5).
During the treatment period 1.5% chil-
dren experienced AEs. The AEs occurred 
in 3 children of the control group. In Den-
tokind® group no AEs occurred. Almost 
all parents and investigators rated the tol-
erability of Dentokind® as “very good” or 
“good”. Compared to the control group 
the outcome in the Dentokind® group was 
significantly better (Armitage Trend Test: 
p<0.0001; FAS).
The study demonstrated that Dentokind® 
reduced total severity scores of subjective 
complaints, including individual symptoms 
such as unmotivated anxiety, gingival ten-
derness, appetite disorders and otalgy in 
teething children after 7 days of treatment. 
Total severity scores of clinical signs also 
lowered after 7 days of treatment in both 
groups. Dentokind®seems therefore a “prag-
matic treatment alternative” to conventional 
OTC teething gels for symptoms relief of 
painful teething in children [21].
upper reSpIrAtory trACt 
InfeCtIonS (urtIs)
definition
Upper respiratory tract infections (UR-
TIs) or common colds represent the most 
frequently occurring illness in the world. 
Although they are usually self-limiting con-
ditions, they are a leading cause of missed 
figure 5. Treatment 
satisfaction on day 7, 
assessed by parents. 
Adapted from [21]
days from work and school, with a relevant 
economic burden [49].
Sore throat, runny nose, general malaise, 
fever, nasal congestion and cough are most 
common symptoms [22].
The specific immune status of children in 
the first years of life makes them especially 
vulnerable to viral infections [50]. In litera-
ture about 4-8 episodes of viral infection per 
year per child are recorded [50]. The major-
ity of URTIs are caused by viral pathogens, 
most commonly rhinoviruses, but also in-
fluenza viruses [22].
URTIs are even the most frequent cause 
of antibiotic prescriptions in pediatric 
outpatient care. This represents a serious 
health problem globally since inappropri-
ate use of antibiotics has a strong impact 
the increase of bacterial respiratory patho-
gens [51,52].
treatment
Since there is no approved specific therapy 
for URTIs, treatment is mainly symptom-
atic. The most common pharmacological 
treatments are antipyretics, anti-inflamma-
tory drugs, expectorants, decongestants, and 
cough suppressants [21]. A number of other 
remedies are available, such as vitamins, 
herbal supplements and homeopathic medi-
cine. Data relating to the Germany showed 
that about 7% of all pediatric prescriptions 
for the respiratory tract system are not offi-
cially licensed for use in children [53].
As mentioned above, a key issue con-
cerns the prescription of antibiotics, that 
are widely prescribed, but often inappro-
priate; overuse can lead to the development 
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of community-acquired resistant pathogens 
which are an increasing and serious health 
burden [50]. The results of a nationwide US 
survey published in 2004 showed 38% of 
more than 6.5 million visits (primary prac-
tice, outpatient, and emergency department) 
by children and adults with a diagnosis of 
influenza were associated with antibiotic 
prescriptions. Studies limited to children 
demonstrated even higher rates of antibiotic 
treatment in children diagnosed with viral 
infections [54].
There are many factors that contribute 
to an inappropriate antibiotic prescription, 
including diagnostic uncertainty, lack of 
knowledge, socio-cultural and economic 
pressures, meeting parental expectations 
[51].
Natural remedies, and homeopathy in 
particular, can be used in the management 
of URTIs. An integrative approach to these 
infections may help reduce excessive antibi-
otic prescription [55].
Influcid® (use and dosage)
Influcid® (Deutsche Homöopathie-
Union, DHU, Karlsruhe, Germany) is a 
homeopathic preparation containing a fixed 
combination of 6 homeopathic singles sub-
stances: Aconitum D3, Bryonia D2, Eupa-
torium perfoliatum D1, Gelsemium D3, 
Ipecacuanha D3 and Phosphorus D5 [56]. 
Launched in Germany in 1928, now it is 
marketed in 22 countries worldwide [22]. 
In acute conditions, and in children below 
12 years, the suggested dose is 1 tablet every 
2 hours, up to a maximum of 8 tablets per 
day, until improvement occurs; for subse-
quent treatment the dose is 1 tablet 3 times 
per day. The same dosage (1 tablet 3 times 
per day) is suggested for prevention of infec-
tions. Tablets should be dissolved slowly in 
the mouth: for small children, they can be 
dissolved in a little bit of water. An interval 
of at least half an hour to meals should be 
kept [56]. 
Efficacy and safety of Influcid® (IFC) in 
the treatment of flu-like infections and UR-
TIs were demonstrated in several studies: in 
the multicenter open study conducted by 
Heger on a total of 600 patients (333 adults 
and 267 children) with URTIs, about 90% 
of patients reported an improvement after 
3 days [57].
from literature
In 2015 a randomized, standard-treat-
ment controlled, parallel group, open, mul-
ticenter and multinational clinical trial was 
published by Thinesse-Mallwitz and col-
leagues [22]. Aim of the study was to eval-
uate the effectiveness and safety of IFC as 
an add-on to symptomatic standard treat-
ments of URTIs. A total of 523 patients 
presenting with clinical signs and symp-
toms of an URTI with a duration up to 24 
h, accompanied by fever were randomized. 
The standard treatment (ST) group received 
paracetamol, ambroxol and/or oxymetazo-
line; the IFC group received the same 
symptomatic treatment plus IFC for 7 days. 
Patients evaluation was performed by in-
figure 6. Between-
group differences in the 
percentage of treatment 
responders (IFC minus 
ST) by study day 
(including 95% CIs) 
Adapted from [22]
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vestigators at baseline (day 1), and on day 
4, 8, 15. During the first 72 hours, patients 
≥ 12 years took 12 tablets a day (1 tablet 
every hour) while patients < 12 years took 
8 tablets per day (1 tablet every 2 hours); 
during the following 96 hours the IFC dos-
age was 2 tablets 3 times a day for patients 
≥ 12 years and 1 tablet 3 times a day for 
children.
The primary outcome was “treatment re-
sponse” defined as a combination of mean 
axillary body temperature ≤ 37.2° C and 
absence or very mild degree of symptoms.
Patients in the IFC group showed an at-
tenuated and shortened course of illness: 
at day 4 a percentage of 76.8% in the IFC 
group was free of fever vs 56.7% in the ST 
group and 17.0% had absence or very mild 
symptoms vs 7.5% of ST group.
Considering the entire study period of 
14 days, data highlighted a more prompt 
occurrence of “treatment response” in the 
IFC group (Figure 6).
As a consequence to the significantly bet-
ter response to treatment, patients in the 
IFC group showed a shorter time to symp-
tom alleviation (1-2 days), a faster resump-
tion of normal activities (IFC 48% vs ST 
28%) (Figure 7) and a significantly lower 
median disease severity. Simultaneously, sig-
nificantly less standard symptomatic medi-
cation was needed in the IFC group (Figure 
8). Safety results confirmed the good toler-
ability of IFC.
figure 7. Ability to 
perform normal daily 
activities. Adapted 
from [22]
figure 8. Cumulated 
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According to authors’ conclusions, IFC 
as an add-on therapy improved response, 
shortened the duration of URTIs, and low-
ered symptoms severity. The results suggest 
that IFC enhanced the self-recovery of the 




Tonsillopharyngitis is an infection of the 
palatine tonsils and pharynx that can be ei-
ther acute or recurrent. Acute pharyngitis is 
caused by Group A beta-hemolytic strep-
tococcus (GABHS) in the 15-30% of cases 
in children, and in 5 to 20 percent in adults 
[58]; the remaining cases are considered vi-
ral [59]. Tonsillopharyngitis is a common 
reason for pediatric health care visits: in the 
USA, approximately 10% of children seen 
by medical care providers each year have 
pharyngitis, and 25-50% of these children 
have GABHS pharyngitis [60]. Among 
school-aged children, the incidences of 
acute sore throat, swab-positive GABHS, 
and serologically confirmed GABHS infec-
tion are 33, 13, and 8 per 100 children/years, 
respectively [58].
The signs and symptoms of acute tonsil-
litis can be similar to other infectious causes 
(e.g. painful swallowing, sore throat, cervical 
lymphadenopathy), while recurrent tonsilli-
tis is characterized by more specific symp-
toms (e.g. enlarged tonsils, caseous detritus 
or liquid pus in the cryps, ridged thickening 
and chronic hyperemia of the edges of the 
palatine arches).
Diagnosis is based on clinical findings. 
To positively identify whether the etiology 
is bacterial or viral, a rapid strept test (RST) 
or a throat swab culture can be performed.
If tonsillopharyngitis is not properly treat-
ed, serious complications, as rheumatic fever 
and related cardiovascular disorders or post-
streptococcal glomerulonephritis, can occur.
treatment
The goals of treatment are to: attenuate the 
severity of symptoms, shorten the course of 
disease, reduce the number of disease-related 
absences in school or at work, help prevent 
serious complications, and improve the qual-
ity of life [61]. The treatment of tonsillitis, 
both in acute and in recurrent form, is based 
on pharmacological measures, as symptom-
atic medications, antipyretics and analgesics, 
and on other measures, as gargling, throat 
compresses, and ultrasound. Only GABHS 
infections diagnosed by RST or culture 
should be treated with antibiotics [62]. Ac-
cording to a recent US study [63], antibiotics 
were prescribed during 60% of pharyngitis 
visits for children, while bacteria are respon-
sible for pharyngitis only in 37% of cases: the 
inappropriate antibiotic treatment, suggest-
ed by this study, is becoming a major issue, 
in relation to development of resistances and 
hypersensitivity. To date, the management of 
bacterial pharyngitis remains controversial, 
and there is a lack of uniformity between 
different guidelines [64].
Tonsillectomy is indicated for repeated 
GABHS tonsillitis and severe acute tonsil-
litis persistent despite antibiotics. Accord-
ing to a recent Cochrane review, the results 
of surgery are controversial: the effects are 
modest, and they should be balanced with 
the risks related to the surgical procedure 
[65].
As for the other URTIs, natural remedies 
and homeopathy are used for tonsillitis 
and pharyngitis: according to data from a 
recent international survey, conducted on 
138 pediatricians, general practitioners and 
ear-nose-throat specialists in 7 countries, 
homeopathic remedies were prescribed as 
a supportive therapy by 62% of participants 
in case of acute tonsillopharyngitis, and by 
59% of participants in case of recurrent ton-
sillopharyngitis [55].
tonsilotren® (use and dosage)
Tonsilotren® (Deutsche Homöopathie 
Union, DHU, Karlsruhe, Germany) is a 
homeopathic complex composed of a com-
bination of 5 single remedies: Atropinum 
sulfuricum D5, Hepar sulfuris D3, Kalium 
bichromicum D4, Mercurius bijodatus D8, 
and Silicea D2 [66]. In acute tonsillitis, the 
suggested dosage for children < 1 year is 1 
tablet (250 mg) 3 times a day; for children 
1-11 years, the initial dose is 1 tablet every 
2 hours (maximum 8 times a day) and the 
subsequent dose is 1 tablet 3 times a day. In 
recurrent tonsillitis, the dosage for children 
< 12 years is 1 tablet 3 times a day: the treat-
ment should continue for 6-8 weeks in 3-4 
treatment cycles per year. Tonsilotren® can 
be used on its own or in combination with 
prescribed medication. An interval of ap-
proximately 30 minutes should be kept be-
tween the intake of Tonsilotren® and eating 
or drinking [66].
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from literature
Tonsilotren® has been studied in a series 
of clinical studies, since the early nineties 
[23,24,67-73]. Here we present the main 
results of the two most recent studies in the 
pediatric setting, one in patients with acute 
tonsillitis [23] and one in patients with re-
current tonsillitis [24].
Friese et al. [23] performed a multicenter, 
randomized, placebo-controlled, double-blind 
study on 158 patients aged 6-10 years affected 
by acute tonsillitis and without indication for 
an antibiotic treatment. The study group re-
ceived Tonsilotren® at dosage of 1 tablet for 
hour (max. 12 times a day) until onset of im-
provement, afterwards the dosage was 1 tab-
let 3 times a day; the control group received 
placebo. The primary outcome criterion was 
the decrease of total sum score of tonsillitis 
typical symptoms from baseline to day 4; the 
5 tonsillitis typical symptoms included diffi-
culties swallowing, pain in throat, salivation, 
reddening and fever, rated on a 4-point-scale. 
Secondary outcome criteria were: the remis-
sion of tonsillitis typical single symptoms as-
sessed on day 4, the time until onset of treat-
ment effect, the outcome of treatment , and 
the safety and tolerability of Tonsilotren®. 
The overall observational period was 6 days.
The decrease of total sum score of tonsil-
litis typical symptoms from baseline to day 
4 was significantly higher in the study group 
(- 7.2 vs - 2.7), as well as the remission of 
tonsillitis typical single symptoms assessed 
on day 4 (Figure 9).
Moreover, 92.4 % of patients showed a 
full recovery or at least a moderate improve-
figure 9. Remission of 
tonsillitis typical single 
symptoms assessed on 
day 4. Adapted by [23]
ment after 6 days of treatment, compared 
to the 43.1 % in the control group. The 
complete recovery rate was 75.9% in the 
study group vs 16.5% in the control group, 
and the deterioration rate was 3.8% in the 
study group vs 22.8% in the control group. 
Tonsilotren® showed an excellent safety and 
tolerability: no adverse event was related to 
the treatment and almost 100% of patients 
and physicians rated the tolerability as “very 
good” or “good”.
The most recent study on Tonsilotren® 
were performed by Palm and colleagues be-
tween January 2013 and April 2015, and the 
results were presented at the 13th Congress 
of the European Society of Pediatric Oto-
rhinolaryngology (ESPO) [24]. A random-
ized, controlled, clinical trial was conducted 
in Germany, Spain and Ukraine on 256 
patients aged 6-60 years (86 ≤ 12 years, 51 
between 12-18 years, 119 ≥ 18 years) with 
moderate recurrent tonsillitis (RT). Conven-
tional symptomatic drugs were allowed to be 
prescribed to all the patients involved, while 
the test group received additionally Tonsi-
lotren® for 3 treatment periods of 8 weeks, 
each treatment period being followed by a 
8 to 12 weeks period without Tonsilotren®. 
The estimated rate of diagnosed acute throat 
infections per year was the primary outcome 
measure; other outcome measures were the 
severity of RT symptoms and the antibiot-
ics consumption due to acute throat infec-
tions. The primary outcome was significantly 
lower in the test group compared to the 
control group (0.59; 95%-CI: 0.41-0.85 vs. 
1.35; 95%-CI: 1.09-1.66; p=0.0002; Poisson 
regression model) [24]. The RT symptoms 
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occurred in a significantly lower percentage 
of patients in the test group compared to 
the control group: difficulties in swallowing 
/ sore throat were seen in 25% of test group 
vs. 52.5% of control group (p<0.0001; Chi2 
test), halitosis in 30.5% vs. 67.5% (p<0.0001; 
Chi2 test) and caseous purulent plugs in 
the tonsillar crypts in 45.3% vs. 66.7% 
(p=0.0007; Chi2 test) [24]. Significantly 
lower was also the antibiotics consumption 
due to acute throat infections: 37% in the test 
group vs. 58.2 in the control group (95%-
CI: 9.13-33.36; p=0.0008; Chi2 test) [24]. 
Positive results were also registered about the 
safety of Tonsilotren®: in the test group 225 
adverse events were reported, three of these 
were related to Tonsilotren® [24].
ConCluSIon
In recent years the use of herbal remedies 
and homeopathic products in children is 
highly increasing, as outlined by analysis 
carried out in the USA and in Europe [3-
6]. Very often parents ask the pediatricians 
to give children these kind of remedies, 
especially in the early childhood years or 
for the treatment of mild ailments, such as 
those related to teething or infantile colic. 
The biggest concern for parents comes gen-
erally from the risk of adverse events due to 
conventional drugs; furthermore, for some 
disorders, there is no standard of care in 
mainstream medicine. In these cases the 
use of homeopathic products confer the 
advantage of having an excellent profile of 
safety and tolerability together with efficacy, 
as demonstrated by recent studies presented 
and discussed in this article [20-24].
Homeopathy can also be useful as adjunc-
tive therapy for conventional drugs: recent 
studies show that, even in children, very of-
ten homeopathic products are used together 
with conventional therapies. In these cases 
the use of homeopathic medicines demon-
strated to alleviate symptoms, contributing 
to shorten the duration of the disease and 
decreasing the use of symptomatic drugs, 
as here reported by the study on Influcid® 
[22]. In some pathologies, in particular, such 
as recurrent respiratory infections in chil-
dren, the use of symptomatic drugs is very 
high, although not particularly effective. A 
recent Cochrane review confirmed the con-
troversial results on non-prescription, over-
the-counter (OTC) medicines for acute 
cough due to URTIs: in the absence of good 
evidence for or against the effectiveness of 
OTC medicines in acute cough, the Authors 
stressed the importance of prescribing these 
drugs with caution, to avoid the risk of ad-
verse events [74].
There is a strong interest of pediatricians 
towards herbal products and homeopathic: 
many studies have reported a growing de-
mand for validated information, also to 
better address the demands and needs of 
patients and their parents [7]. In recent 
years it has also increased the number of 
pediatricians and physicians who choose to 
treat themselves with natural and homeo-
pathic remedies.
Although homeopathy is still debated, 
there are some studies that attest to the ef-
ficacy and safety in children. In this article 
we present and discuss five studies that have 
shown the effectiveness of homeopathic 
products for the treatment of infantile colic, 
teething, URTIs and tonsillopharyngitis 
[20-24]. As authors active in clinical practice 
we hope that such issues will be investigated 
with further trials and updated reviews on 
existing literature.
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